<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26896318</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Intravenous magnesium sulfate for the management of severe hand, foot, and mouth disease with autonomic nervous system dysregulation in Vietnamese children: study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>98</StartPage><MedlinePgn>98</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">98</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-016-1215-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Over the last 15 years, hand, foot, and mouth disease (HFMD) has emerged as a major public health burden across the Asia-Pacific region. A small proportion of HFMD patients, typically those infected with enterovirus 71 (EV71), develop brainstem encephalitis with autonomic nervous system (ANS) dysregulation and may progress rapidly to cardiopulmonary failure and death. Although milrinone has been reported to control hypertension and support myocardial function in two small studies, in practice, a number of children still deteriorate despite this treatment. Magnesium sulfate (MgSO4) is a cheap, safe, and readily available medication that is effective in managing tetanus-associated ANS dysregulation and has shown promise when used empirically in EV71-confirmed severe HFMD cases.</AbstractText><AbstractText Label="METHODS/DESIGN" NlmCategory="METHODS">We describe the protocol for a randomized, placebo-controlled, double-blind trial of intravenous MgSO4 in Vietnamese children diagnosed clinically with HFMD plus ANS dysregulation with systemic hypertension. A loading dose of MgSO4 or identical placebo is given over 20 min followed by a maintenance infusion for 72 h according to response, aiming for Mg levels two to three times the normal level in the treatment arm. The primary endpoint is a composite of disease progression within 72 h defined as follows: development of pre-specified blood pressure criteria necessitating the addition of milrinone, the need for ventilation, shock, or death. Secondary endpoints comprise these parameters singly, plus other clinical endpoints including the following: requirement for other inotropic agents; duration of hospitalization; presence of neurological sequelae at discharge in survivors; and neurodevelopmental status assessed 6 months after discharge. The number and severity of adverse events observed in the two treatment arms will also be compared. Based on preliminary data from a case series, and allowing for some losses, 190 patients (95 in each arm) will allow detection of a 50 % reduction in disease progression with 90 % power at a two-sided 5 % significance level.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Given the large numbers of HFMD cases currently being seen in hospitals in Asia, if MgSO4 is shown to be effective in controlling ANS dysregulation and preventing severe HFMD complications, this finding would be important to pediatric care throughout the region.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier: NCT01940250 (Registered 22 August 2013).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qui</LastName><ForeName>Phan Tu</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. phantuqui@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. phantuqui@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanh</LastName><ForeName>Truong Huu</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Children's Hospital Number 1, 341 S&#x1b0; V&#x1ea1;n H&#x1ea1;nh, District 10, Ho Chi Minh City, Vietnam. truonghuukhanh@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trieu</LastName><ForeName>Huynh Trung</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. huynhtrieu82@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giang</LastName><ForeName>Ph&#x1ea1;m Thanh</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. chuotchui1007@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bich</LastName><ForeName>Nguyen Ng&#x1ecd;c</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. drngocbich@yahoo.com.vn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thoa</LastName><ForeName>Le Phan Kim</ForeName><Initials>le PK</Initials><AffiliationInfo><Affiliation>Children's Hospital Number 1, 341 S&#x1b0; V&#x1ea1;n H&#x1ea1;nh, District 10, Ho Chi Minh City, Vietnam. thoalephan@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nhan</LastName><ForeName>Le Nguyen Thanh</ForeName><Initials>le NT</Initials><AffiliationInfo><Affiliation>Children's Hospital Number 1, 341 S&#x1b0; V&#x1ea1;n H&#x1ea1;nh, District 10, Ho Chi Minh City, Vietnam. drnhanbvnhidong1@yahoo.com.vn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabanathan</LastName><ForeName>Saraswathy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. saras.whitehorn@googlemail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX1 2JD, UK. saras.whitehorn@googlemail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Doorn</LastName><ForeName>Rogier</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. hrogier@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX1 2JD, UK. hrogier@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toan</LastName><ForeName>Nguyen Duc</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. toannd@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merson</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. lmerson@oucru.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX1 2JD, UK. lmerson@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dung</LastName><ForeName>Nguyen Thi Phuong</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. dungntp@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanh</LastName><ForeName>Lam Phung</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. lampk@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolbers</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. mwolbers@oucru.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX1 2JD, UK. mwolbers@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Nguyen Thanh</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Children's Hospital Number 1, 341 S&#x1b0; V&#x1ea1;n H&#x1ea1;nh, District 10, Ho Chi Minh City, Vietnam. drthanhhung@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Nguyen Van Vinh</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. chaunvv@oucru.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Bridget</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. bwills@oucru.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX1 2JD, UK. bwills@oucru.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01940250</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7487-88-9</RegistryNumber><NameOfSubstance UI="D008278">Magnesium Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU9YAX04C7</RegistryNumber><NameOfSubstance UI="D020105">Milrinone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007258" MajorTopicYN="N">Informed Consent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008278" MajorTopicYN="N">Magnesium Sulfate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020105" MajorTopicYN="N">Milrinone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26896318</ArticleId><ArticleId IdType="pmc">PMC4759733</ArticleId><ArticleId IdType="doi">10.1186/s13063-016-1215-6</ArticleId><ArticleId IdType="pii">10.1186/s13063-016-1215-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;90. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietnam Ministry of Health: Health Statistics Yearbook 2011. Hanoi: Medical Publisher; 2012:175&#x2013;76</Citation></Reference><Reference><Citation>WHO. A Guide to Clinical Management and Public Health Response for Hand Foot Mouth Disease (HFMD) 2010.http://www.wpro.who.int/emerging_diseases/documents/HFMDGuidance/en/. Accessed 2 Dec 2011.</Citation></Reference><Reference><Citation>Fu YCCC, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, et al. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child. 2004;89:368&#x2013;73. doi: 10.1136/adc.2003.029645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.2003.029645</ArticleId><ArticleId IdType="pmc">PMC1719879</ArticleId><ArticleId IdType="pubmed">15033850</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, Huang FL, Chang Y. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child. 2004;89(4):368&#x2013;73. PubMed PMID: 15033850; PubMed Central PMCID: PMC1719879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1719879</ArticleId><ArticleId IdType="pubmed">15033850</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YC, Chi CS, Lin NN, Cheng CC, Jan SL, Hwang B, Hsu SL, Gong CL, Chen YT, Chiu YT. Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. Pediatr Cardiol. 2006;27(5):577-84. PubMed PMID: 16933070.</Citation><ArticleIdList><ArticleId IdType="pubmed">16933070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-M, Lei H-Y, Yu C-K, Wang J-R, Su I-J, Liu C-C. Acute Chemokine Response in the Blood and Cerebrospinal Fluid of Children with Enterovirus 71&#x2013;Associated Brainstem Encephalitis. J Infect Dis. 2008;198:1&#x2013;5. doi: 10.1086/591462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/591462</ArticleId><ArticleId IdType="pubmed">18710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubcevic J, Waki H, Raizada MK, Paton JFR. Autonomic-Immune-Vascular Interaction: An Emerging Concept for Neurogenic Hypertension. Hypertension. 2011;57:1026&#x2013;33. doi: 10.1161/HYPERTENSIONAHA.111.169748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.111.169748</ArticleId><ArticleId IdType="pmc">PMC3105900</ArticleId><ArticleId IdType="pubmed">21536990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang MC, Wu JM, Chen CT, Wang JN, et al. Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol. 2005;39:219&#x2013;23. doi: 10.1002/ppul.20157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.20157</ArticleId><ArticleId IdType="pubmed">15635619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi CY, Khanh TH, le PK T, Tseng FC, Wang SM, Thinh le Q, et al. Milrinone Therapy for Enterovirus 71-Induced Pulmonary Edema and/or Neurogenic Shock in Children: A Randomized Controlled Trial. Crit Care Med. 2013;41:1&#x2013;7. doi: 10.1097/CCM.0b013e31828a2a85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2a85</ArticleId><ArticleId IdType="pubmed">23685637</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietnamese Ministry of Health: Guideline for HFMD Management. H&#xe0; N&#x1ed9; i, 2012.http://benhnhietdoi.vn/data/files/documents/QD.1003.BYT.20.3.2012_Huong_dan_chan_doan_va_dieu_tri_benh_tay_chan_mieng.pdf.Accessed 9 April 2012.</Citation></Reference><Reference><Citation>Drugs.com. Milrinone injection - FDA prescribing information, side effects and uses. http://www.drugs.com/pro/milrinone-injection.html. Accessed 16 Feb 2016.</Citation></Reference><Reference><Citation>Smith AH, Owen J, Borgman KY, Fish FA, Kannankeril PJ. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol. 2011;108:1620&#x2013;4. doi: 10.1016/j.amjcard.2011.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2011.07.023</ArticleId><ArticleId IdType="pmc">PMC3941037</ArticleId><ArticleId IdType="pubmed">21890079</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites CL, Yen LM, Cordon SM, Thwaites GE, Loan HT, Thuy TT, et al. Effect of magnesium sulphate on urinary catecholamine excretion in severe tetanus. Anaesthesia. 2008;63:719&#x2013;25. doi: 10.1111/j.1365-2044.2008.05476.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.2008.05476.x</ArticleId><ArticleId IdType="pubmed">18582257</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites CL, Yen LM, Cordon SM, Binh NT, Nga NTN, White NJ, et al. Urinary catecholamine excretion in tetanus. Anaesthesia. 2006;61:355&#x2013;9. doi: 10.1111/j.1365-2044.2006.04580.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.2006.04580.x</ArticleId><ArticleId IdType="pubmed">16548955</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites CL, Yen LM, Loan HT, Thuy TT, Thwaites GE, Stepniewska K, Soni N, White NJ, Farrar JJ. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-43. PubMed PMID: 17055945.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055945</ArticleId></ArticleIdList></Reference><Reference><Citation>James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth Analg. 1989;68:772&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2735543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe BHBJ, Bourdon C, Bota G, Blitz S, Camargo CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department (Review) The Cochrane Library. 2009;3:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10167721</ArticleId><ArticleId IdType="pubmed">10796650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch Dis Child. 1995;72:F184&#x2013;7. doi: 10.1136/fn.72.3.F184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/fn.72.3.F184</ArticleId><ArticleId IdType="pmc">PMC2528455</ArticleId><ArticleId IdType="pubmed">7796235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones NAJS. Management of life-threatening autonomic hyper-reflexia using magnesium sulphate in a patient with a high spinal cord injury in the intensive care unit. Br J Anaesth. 2002;88:434&#x2013;8. doi: 10.1093/bja/88.3.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/88.3.434</ArticleId><ArticleId IdType="pubmed">11990279</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehama TIH, Kanazawa K. Management of autonomic hyperreflexia with magnesium sulfate during labor in a woman with spinal cord injury. Am J Obstet Gynecol. 2000;183:492&#x2013;3. doi: 10.1067/mob.2000.104230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mob.2000.104230</ArticleId><ArticleId IdType="pubmed">10942492</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth RMSP, Armstrong N, Duley L. Magpie Trial in the UK: methods and additional data for women and children at 2&#xa0;years following pregnancy complicated by pre-eclampsia. BMC Pregnancy Childbirth. 2009;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679706</ArticleId><ArticleId IdType="pubmed">19366459</ArticleId></ArticleIdList></Reference><Reference><Citation>Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Asp Med. 2003;24:107&#x2013;36. doi: 10.1016/S0098-2997(02)00094-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0098-2997(02)00094-8</ArticleId><ArticleId IdType="pubmed">12537992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez Kitchen CM, Funderburg N, et al. Magnesium Decreases Inflammatory Immunomodulatory Mechanism: A Novel Innate Cytokine Production. J Immunol. 2012;188:6338&#x2013;46. doi: 10.4049/jimmunol.1101765.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101765</ArticleId><ArticleId IdType="pmc">PMC3884513</ArticleId><ArticleId IdType="pubmed">22611240</ArticleId></ArticleIdList></Reference><Reference><Citation>Muroi CBJ, Hugelshofer M, Seule M, Mishima K, Keller E. Magnesium and the inflammatory response: potential pathophysiological implications in the management of patients with aneurysmal subarachnoid hemorrhage? Magnes Res. 2012;25:64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">22966500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JJRG. Magnesium sulfate for persistent pulmonary hypertension of the newborn. The Cochrane Library. 2010; 3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8896076</ArticleId><ArticleId IdType="pubmed">17636807</ArticleId></ArticleIdList></Reference><Reference><Citation>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics. 2004; 114:555.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn JT. Management of hypertensive emergencies and urgencies in children. http://www.uptodate.com/contents/management-of-hypertensive-emergencies-and-urgencies-in-children?source=search_result&amp;search=Management+of+hypertensive+emergencies+and+urgencies+in+children&amp;selectedTitle=1%7E150. Accessed 16 Nov 2012.</Citation></Reference><Reference><Citation>National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). version 4.03. 2010.http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 17 Feb 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>